Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
Yoshiya TanakaAyako YamaguchiToshiaki MiyamotoKazuhide TanimuraHideyuki IwaiYuko KanekoTsutomu TakeuchiKoichi AmanoNaoki IwamotoAtsushi KawakamiMiho MurakamiNorihiro NishimotoTatsuya AtsumiTakayuki SumidaKoichiro OhmuraTsuneyo MimoriHisashi YamanakaKeishi FujioYoshihisa FujinoKazuyoshi SaitoKazuhisa NakanoShintaro HirataShingo NakayamadaPublished in: Rheumatology (Oxford, England) (2022)
After achieving sustained remission by combination treatment of MTX/bDMARDs, disease control was achieved comparably by continuation, dose reduction or discontinuation of MTX and dose reduction of bDMARDs at end of year 1. Subsequent de-escalation of MTX had no impacts on disease control but decreased adverse events in year 2.